# Piramal Pharma Ltd (PPLPHARMA)
> Exchange: NSE | Sector: Pharma | ISIN: 

## Price
Current Price: ₹175.63
Day Change: -0.26%
52W High: ₹220.85
52W Low: ₹132.3
Market Cap: ₹23,064 Cr

## Valuation
P/E: 0
P/B: 2.85
EPS: ₹-2.47
Book Value: ₹61.03
Dividend Yield: 0%

## Returns
1Y Return: -10.49%

## Profitability
ROE: -4%
ROCE: 0.72%
Debt/Equity: 0.7
Revenue Growth: -0.1%
Profit Growth: 0%
EBITDA Margin: 9.86%
Operating Margin: 8.8%

## About
Piramal Pharma Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Sector: Pharma
Industry: Drug Manufacturers - Specialty & Generic
Sub Industry: Unknown

## Business Model
Overview: Piramal Pharma Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Domestic formulations
- Exports and regulated markets
- Specialty or institutional sales
Operating Model:
- Develops, manufactures, distributes, or services healthcare products across regulated channels.
- Approvals, product mix, compliance quality, and R&D productivity shape growth.
Recent Context:
- Announcement: Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
- Announcement: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- CNW Group: Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility

## Access
Current tier: anonymous
More history: Register free to see 2 more years.

## Data Freshness
Quote Updated: 2026-05-24T20:00:14.481Z
Price History Updated: 2026-05-18T22:58:15.781Z
Latest Price History Date: 2026-05-18
Technicals Updated: 2026-05-18T22:58:15.781Z
Quant Updated: 2026-05-18T22:58:15.781Z
Sentiment Updated: 2026-05-18T22:58:15.781Z
Financials Status: current
Financials Updated: 2026-05-18T08:31:50.157Z
Financials Last Attempt: 2026-05-18T08:31:50.157Z
Financials Provider Tried: yahoo
Latest P&L Period: FY26
Latest Balance Sheet Period: FY26
Latest Cash Flow Period: FY26

## P&L (Mar 2022)
Revenue: ₹6315 Cr
Operating Profit: ₹1428 Cr (OPM 23%)
Net Profit: ₹835 Cr
Tax: ₹949 Cr

## Annual P&L History
Mar 2022: Rev ₹6315Cr | PAT ₹835Cr | OPM 23%
Mar 2023: Rev ₹6559Cr | PAT ₹376Cr | OPM 14%
Mar 2024: Rev ₹7082Cr | PAT ₹-186Cr | OPM 9%

## Balance Sheet (Mar 2022)
Total Assets: ₹10677 Cr
Total Liabilities: ₹10677 Cr
Borrowings: ₹3025 Cr
Cash: ₹undefined Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Nandini Ajay Piramal, Executive Chairperson
- Vivek  Valsaraj, CFO & Executive Director
- Peter Daniel DeYoung, CEO of Piramal Global Pharma & Director
- Vinay  Agarwal, Senior Vice President of Operations
- Viral  Gandhi, President & Group CIO of Piramal Group

---
Source: rupiya.io/stocks/pplpharma
Disclaimer: For research and education only. Not investment advice.